Influenza A+B and COVID-19 Combo Rapid Test: Turnaround Time, Workflow and Practical Considerations

· By Lisa Zhang, Export Sales Manager · QL Biotek Export Team

Why turnaround time matters in respiratory testing

During peak respiratory virus seasons, the clinical value of a rapid test is measured less by its packaging and more by how fast a usable answer reaches the person holding the swab. Symptoms of influenza A, influenza B and COVID-19 overlap to a degree that makes visual diagnosis unreliable, yet the treatment pathways diverge: antiviral therapy for influenza, different clinical management for COVID-19, and supportive care in many other cases.

A combo rapid test that resolves all three targets from one sample in a single sitting removes that ambiguity. For importers, distributors and IVD manufacturers, this is the core commercial argument: one SKU replaces three, and the short read time makes the product suitable for pharmacies, workplaces, clinics and home use alike.

Result time: what to expect

Results from a combined Influenza A, Influenza B and COVID-19 rapid test are typically available in approximately 15 minutes after the sample has been applied to the device. The reading window is the practical specification to communicate to end users: apply the prepared sample, start a timer, and interpret the lines within the stated interval.

Three timing details deserve emphasis in product documentation and training materials:

  • Do not read before the minimum time. Reading too early can miss a faint positive line.
  • Do not read after the maximum time. Late reading can produce evaporation lines that mimic a positive result.
  • Interpret each antigen line independently. A specimen can be positive for more than one target, and the device is designed to display each result separately.

The workflow, step by step

The procedure is deliberately short so that it can be performed without professional supervision. Each kit ships with instructions covering the full sequence:

  1. Collect a nasal swab sample using the swab supplied in the kit.
  2. Insert the swab into the provided preparation solution and mix it to release the viral antigens.
  3. Apply the solution to the sample well of the test strip or cassette.
  4. Wait approximately 15 minutes and read the result.

Because the process involves no instrument, no cold chain during use and no laboratory step, it fits a range of distribution channels — retail pharmacy, online sales, occupational health programs and primary care settings. The simplicity also supports high user compliance, which in turn supports the accuracy figures achieved in real-world use.

Accuracy and quality control

Accuracy is the second specification buyers evaluate after speed. Combo rapid tests of this class are reported to deliver high sensitivity and specificity across all three targets, with accuracy rates often exceeding 90 percent. Behind that figure sits batch-level quality control: each lot is checked against reference materials before release, and manufacturers align production with the standards applicable to this product category.

For distributors, it is worth requesting the analytical performance data and the regulatory documentation for each market at the quotation stage. Clearance or registration status varies by country, and the paperwork must match the destination market before shipment.

Who the test is designed for

The device is intended for use in adults and in children from two years of age upward, which makes it practical for household-level testing where several age groups share a single kit. The inclusion of young children matters because pediatric influenza cases are a significant driver of seasonal healthcare demand.

Equally important is the role of rapid testing in vulnerable populations — older adults and immunocompromised individuals. Early identification allows earlier clinical intervention and can reduce the likelihood of severe complications. Distributors supplying community organizations, long-term care facilities or pharmacy chains should therefore plan inventory around seasonal peaks, when demand from these segments concentrates.

Differentiation drives the treatment decision

The commercial and clinical logic of a combo test rests on differential diagnosis. Confirming whether a symptomatic patient has influenza A, influenza B or COVID-19 determines whether antiviral medication is appropriate, whether COVID-19-specific management applies, or whether neither is warranted. Without differentiation, treatment becomes empirical and medication use rises unnecessarily.

On a population scale, aggregated test results also give health authorities a clearer picture of which virus is circulating at a given moment, supporting resource allocation and public advisories during the season.

What this means for supply and positioning

A product that returns three results in one sample, in about 15 minutes, with no equipment, has a straightforward positioning: it reduces the number of SKUs a distributor must carry, shortens the diagnostic pathway for the end user, and keeps symptomatic individuals out of waiting rooms during periods of peak demand. For IVD manufacturers evaluating OEM or private-label opportunities, the same format supports a compact product line built around a single platform.

QL Biotek supplies the Influenza A+B COVID Combo Rapid Test with the associated instructions, controls and documentation required for export markets. Technical files, performance data and packaging configurations are available on request for importers and distribution partners planning their seasonal procurement.

FAQ

How fast do results appear on the Influenza A+B COVID Combo Rapid Test?

Results are available approximately 15 minutes after the prepared sample is applied to the test strip. Results should be read within the interval specified in the instructions — neither earlier nor later.

Can one test identify more than one virus at the same time?

Yes. The combo format detects Influenza A, Influenza B and COVID-19 from a single nasal swab sample, and each target is displayed on its own line. It is possible for a sample to return more than one positive result.

What age groups can use the test?

The test is designed for use in adults and in children from two years of age upward. For young children, an adult should perform the swabbing following the instructions supplied with the kit.

Talk to a real person. Questions about this topic, IFUs, samples or pricing? Contact Lisa Zhang (Export Sales Manager) — official quotation within 24 hours.

WhatsApp +86 153 0654 9980 Email Enquiry